Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.
The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said.
Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin.
Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January.
Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial.
Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone.
The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies.
Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
Yahoo
an hour ago
- Yahoo
Russia says it tests new laser defences against drones
MOSCOW (Reuters) -Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.
Yahoo
2 hours ago
- Yahoo
Russia says it tests new laser defences against drones
MOSCOW (Reuters) -Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.
